Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MD Anderson Cancer Center
Research
Psilocybin proves promising in neuropathic pain mouse study
Giving psilocybin prior to chemotherapy prevented the development of pain hypersensitivity, with protection maintained up to 8 months in mice.
Marissa Russo
Sep 3, 2026 2:00pm
Quest Diagnostics taps MD Anderson for cancer risk blood test
Jun 10, 2025 2:11pm
BD to study HPV self-collection in underserved Texas communities
Nov 21, 2024 10:45am
MD Anderson launches cell therapy institute with $80M
Nov 11, 2024 4:20pm
Generate raises huge $273M series C, a little short of 2021 haul
Sep 14, 2023 6:00am
Alaunos winds down sole cell therapy trial, cuts 60% of staff
Aug 15, 2023 10:53am
